| 1 |
Josowitz AD, Bindra RS, Saltzman WM. Polymer nanocarriers for targeted local delivery of agents in treating brain tumors. Nanotechnology 2022;34. [PMID: 36179653 DOI: 10.1088/1361-6528/ac9683] [Reference Citation Analysis]
|
| 2 |
Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Curr Treat Options Oncol 2022;23:1566-89. [PMID: 36242713 DOI: 10.1007/s11864-022-01024-5] [Reference Citation Analysis]
|
| 3 |
Pandey N, Anastasiadis P, Carney CP, Kanvinde PP, Woodworth GF, Winkles JA, Kim AJ. Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. Adv Drug Deliv Rev 2022;:114415. [PMID: 35787387 DOI: 10.1016/j.addr.2022.114415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Li R, Wang H, Liang Q, Chen L, Ren J. Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies. Biomater Sci 2022. [PMID: 34989724 DOI: 10.1039/d1bm01401c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 5 |
Alghamri MS, Banerjee K, Mujeeb AA, Taher A, Thalla R, Mcclellan BL, Varela ML, Stamatovic SM, Martinez-revollar G, Andjelkovic-zochowska A, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Olin MR, Lahann J, Lowenstein PR, Castro MG. Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy.. [DOI: 10.1101/2021.08.27.457953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Khater AR, Abou-Antoun T. Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment. Front Cell Dev Biol 2021;9:654103. [PMID: 34055785 DOI: 10.3389/fcell.2021.654103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Metselaar DS, du Chatinier A, Stuiver I, Kaspers GJL, Hulleman E. Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments. Front Oncol 2021;11:662209. [PMID: 33869066 DOI: 10.3389/fonc.2021.662209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 8 |
Zhang Z, Ma J, Xu Y, Zhang H. Observation of the impact of the eight-step process combined with the four-track crossover quality control applied to patients with glioma surgery: a randomised trial. Ann Transl Med 2021;9:696. [PMID: 33987394 DOI: 10.21037/atm-21-1228] [Reference Citation Analysis]
|
| 9 |
Ullrich SJ, Freedman-Weiss M, Ahle S, Mandl HK, Piotrowski-Daspit AS, Roberts K, Yung N, Maassel N, Bauer-Pisani T, Ricciardi AS, Egan ME, Glazer PM, Saltzman WM, Stitelman DH. Nanoparticles for delivery of agents to fetal lungs. Acta Biomater 2021;123:346-53. [PMID: 33484911 DOI: 10.1016/j.actbio.2021.01.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 10 |
Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, Lowenstein PR, Castro MG, Lahann J. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun 2020;11:5687. [PMID: 33173024 DOI: 10.1038/s41467-020-19225-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 24.7] [Reference Citation Analysis]
|
| 11 |
Stegen B, Nieto A, Albrecht V, Maas J, Orth M, Neumaier K, Reinhardt S, Weick-Kleemann M, Goetz W, Reinhart M, Parodi K, Belka C, Niyazi M, Lauber K. Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. Radiat Oncol 2020;15:19. [PMID: 31969174 DOI: 10.1186/s13014-020-1470-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 12 |
Bonner K, Borlay D, Kutten O, Quick QA. Inhibition of the Spectraplakin Protein Microtubule Actin Crosslinking Factor 1 Sensitizes Glioblastomas to Radiation. Brain Tumor Res Treat 2020;8:43-52. [PMID: 32390353 DOI: 10.14791/btrt.2020.8.e1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, Lowenstein PR, Castro MG, Lahann J. Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy.. [DOI: 10.1101/862581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 14 |
Seo YE, Suh HW, Bahal R, Josowitz A, Zhang J, Song E, Cui J, Noorbakhsh S, Jackson C, Bu T, Piotrowski-Daspit A, Bindra R, Saltzman WM. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 2019;201:87-98. [PMID: 30802686 DOI: 10.1016/j.biomaterials.2019.02.016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 15 |
Lopez Sambrooks C, Baro M, Quijano A, Narayan A, Cui W, Greninger P, Egan R, Patel A, Benes CH, Saltzman WM, Contessa JN. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Res 2018;78:5094-106. [PMID: 30026325 DOI: 10.1158/0008-5472.CAN-18-0505] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 16 |
Baro M, Lopez Sambrooks C, Quijano A, Saltzman WM, Contessa J. Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clin Cancer Res 2019;25:784-95. [PMID: 29967251 DOI: 10.1158/1078-0432.CCR-18-0792] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 17 |
Chen EM, Quijano AR, Seo YE, Jackson C, Josowitz AD, Noorbakhsh S, Merlettini A, Sundaram RK, Focarete ML, Jiang Z, Bindra RS, Saltzman WM. Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials 2018;178:193-203. [PMID: 29936153 DOI: 10.1016/j.biomaterials.2018.06.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 18 |
Shaik S, Kennis B, Maegawa S, Schadler K, Yanwen Y, Callegari K, Lulla RR, Goldman S, Nazarian J, Rajaram V, Fangusaro J, Gopalakrishnan V. REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget 2018;9:5233-50. [PMID: 29435175 DOI: 10.18632/oncotarget.23750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Quijano E, Bahal R, Ricciardi A, Saltzman WM, Glazer PM. Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities. Yale J Biol Med 2017;90:583-98. [PMID: 29259523] [Reference Citation Analysis]
|
| 20 |
Seo YE, Bu T, Saltzman WM. Nanomaterials for convection-enhanced delivery of agents to treat brain tumors. Curr Opin Biomed Eng 2017;4:1-12. [PMID: 29333521 DOI: 10.1016/j.cobme.2017.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
